Cargando…
Neoadjuvant checkpoint inhibition in non-small cell lung cancer: Is earlier unquestionably better than later?
On March 4th 2022, nivolumab received regular US Food and Drug Administration approval, based on the CheckMate 816 trial results, for use “with platinum-doublet chemotherapy for adult patients with resectable NSCLC in the neoadjuvant setting”. This is the first neoadjuvant approval of a checkpoint i...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Neoplasia Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381437/ https://www.ncbi.nlm.nih.gov/pubmed/35953223 http://dx.doi.org/10.1016/j.tranon.2022.101505 |